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Available online 12 July 2016Loss-of-function mutations in the Notch ligand, Jagged1 (Jag1), result in multi-system developmental
pathologies associated with Alagille syndrome (ALGS). ALGS patients present with skeletal manifestations
including hemi-vertebrae, reduced bone mass, increased fracture incidence and poor bone healing. However, it
is not known whether the increased fracture risk is due to altered bone homeostasis (primary) or nutritional
malabsorption due to chronic liver disease (secondary). To determine the signiﬁcance of Jag1 loss in bone, we
characterized the skeletal phenotype of two Jag1-ﬂoxed conditional knockout mouse models: Prx1-Cre;Jag1f/f
to target osteoprogenitor cells and their progeny, and Col2.3-Cre;Jag1f/f to target mid-stage osteoblasts
and their progeny. Knockout phenotypes were compared to wild-type (WT) controls using quantitative micro-
computed tomography, gene expression proﬁling and mechanical testing. Expression of Jag1 and the Notch
target genes Hes1 and Hey1 was downregulated in all Jag1 knockout mice. Osteoblast differentiation genes
were downregulated in whole bone of both groups, but unchanged in Prx1-Cre;Jag1f/f cortical bone. Both
knockout lines exhibited changes in femoral trabecular morphology including decreased bone volume
fraction and increased trabecular spacing, withmales presenting amore severe trabecular osteopenic phenotype.
Prx1-Cre;Jag1f/fmice showed an increase inmarrowmesenchymal progenitor cell number and, counterintuitive-
ly, developed increased cortical thickness resulting from periosteal expansion, translating to greater mechanical
stiffness and strength. Similar alterations in femoral morphology were observed in mice with canonical Notch
signaling disrupted using Prx1-Cre-regulatable dominant-negative mastermind like-protein (dnMAML). Taken
together, we report that 1) Jag1 negatively regulates the marrow osteochondral progenitor pool, 2) Jag1 is re-
quired for normal trabecular bone formation and 3) Notch signaling through homotypic Jag1 signaling in
osteochondral progenitors, but not mature osteoblasts, inhibits periosteal expansion. Therefore, Jag1 signaling
within the osteoblast lineage regulates bone metabolism in a compartment-dependent manner. Moreover, loss
of Jag1 function in osteoblast lineage cells may contribute to the skeletal phenotype associated with ALGS.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Bone QCT/μCT1. Introduction
The Notch signaling pathway is a highly conserved cell-cell signaling
mechanism regulating developmental processes including proliferation,, Hepatology and Nutrition, The
, Philadelphia, PA 19104, United
s).
ript.
. This is an open access article underdifferentiation and cell fate determination [1]. Activation of this
pathway occurs when a Notch ligand (Jagged 1, 2 or Delta-like 1, 3, or
4) expressed on the surface of a signaling cell interacts with a Notch
receptor (Notch 1–4) expressed on the surface of a receiving cell. The
Notch intracellular domain (NICD) is liberated via amulti-stage proteolyt-
ic event mediated ﬁrst by the metalloproteinase, ADAM17, and then by
the γ-secretase complex, comprised of Presenilins 1 and 2 (Psen 1, 2).
Cleaved NICD translocates to the nucleus where it binds to RBPJκ,
converting the function of RBPJκ froma transcriptional repressor to an ac-
tivator. Mastermind-like proteins (MAML) then bind to the NICD-RBPJκ
complex and serve as a scaffold to recruit other co-activators necessarythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and Hey [2,3].
Loss-of-function mutations in the Notch ligand gene, JAG1, are re-
sponsible for Alagille syndrome (ALGS) in humans [4,5], inducing
multi-organ developmental defects, most notably bile duct paucity in
the liver, congenital heart defects and skeletal anomalies [6]. ALGS pa-
tients present clinically with decreased bone mass [7] and increased
risk of long bone fracture [8], traits historically assumed to be secondary
to chronic cholestasis and malabsorption of fat-soluble vitamins and
other dietary nutrients. However, recent liver-speciﬁc Notch knockout
models have revealed that Notch signaling deﬁciencies impair
hepatobiliary development and regeneration, but alterations in bone
formation or structure are not reported [9–11]. Further supporting a
direct bone-speciﬁc role for Jag1-mediatedNotch signaling in regulating
bone formation, a genome-wide association study identiﬁed a polymor-
phism at the JAG1 locus as a heritable factor predisposing certain non-
ALGS individuals and populations to low bone mineral density and
high risk of osteoporotic fracture [12].
Notch signaling regulates bone development and maturation in a
context-speciﬁc manner [13,14]. Deletion of Notch1 and Notch2 in
mesenchymal progenitor cells (Prx1-Cre;Notch1−/fNotch2f/f) or similar
deletion of Psen1 and Psen2 (Prx1-Cre;Psen1f/fPsen2−/−) stimulates
osteoblast differentiation and early trabecular bone formation, which
is ultimately lost during aging due to depletion of the progenitor pool
and increased osteoclast activity [15]. Deletion of Notch receptors or
Psen in committed osteoblasts (Col2.3-Cre;Psen1f/fPsen2−/−) [16] or
mature osteoblasts (Ocn-Cre;Notch1f/f) [17] does not alter early bone
formation, but results in osteopenia during aging. Considered together,
early expression of Notch components maintains progenitors in an un-
differentiated state, but expression of these same components in cells
that are committed to the osteoblast lineage supports their anabolic
function. Indeed, overexpression of NICD in mature osteocytes results
in increases in both trabecular and cortical bone volume, as well as
enhanced canonical Wnt signaling and downregulated osteoclast
activity [20]. Global deletion of the Notch target gene Hey1 also results
in osteopenia [21]. Notch also has context speciﬁc effects on osteoclasts.
Notch inhibits osteoclast commitment, but once osteoclasts are
committed, Notch signaling enhances osteoclast maturation and func-
tion [18,19]. These results conclusively demonstrate a developmentally
and temporally dependent role of Notch in bone development and
homeostasis; however, the roles of speciﬁc Notch ligands during
embryological bone development and maturation are still incompletely
understood.
Jag1 is the most highly expressed Notch ligand during skeletal
development [22] and healing [23], and its expression persists within
osteoblast progenitor cell populations throughout their lifespan [24].
High Jag1 expression in mouse osteochondral progenitor cells gradually
decreases during chondrogenic differentiation [25], whereas Jag1 is
expressed at multiple stages of osteoblast differentiation [23]. Jag1
expression in the mesenchymal lineage also regulates hematopoietic
cell behavior [26]. Activation of parathyroid hormone and its receptor
in osteoblast-lineage cells increases Jag1 expression, which then
promotes hematopoietic stem cell expansion [27]. Co-culture of Jag1-
expressing stromal cells with bone marrow-derived macrophages in-
hibits osteoclast differentiation [28]. Targeted deletion of Jag1 in cranial
neural crest cells usingWnt1-Cre causesmaxillary hypoplasia as a result
of delayed ossiﬁcation, decreased bonemineral density and reduced ex-
pression of osteoblast regulators [29,30]. Work in our group has shown
Jag1 to be highly expressed in mesenchymal lineage cells during bone
fracture healing [23] and that Jag1 can induce osteoblast differentiation.
Wang et al. recently reported that loss of Notch signaling in progenitor
cells, but not osteoblasts or chondrocytes, precludes fracture union
[31]. Collectively, the data suggest that Jag1 positively regulates bone
formation and may inhibit resorption. However, the role of Jag1 in
osteoprogenitor cell-mediated long bone development and remodeling
has not been adequately investigated.The objective of this study was to determine the context-speciﬁc
role of Jag1 during bone formation by using two skeletal-speciﬁc condi-
tional Jag1 knockout mouse models: speciﬁcally, early- and late-stage
differentiation. Herein, we show that Jag1 expression and signaling in
osteoblast lineage cells directly alters bone geometry and bone mass.2. Methods
2.1. Generation of mice
Jag1f/f mice [9] were crossed with mice expressing Cre recombinase
(+/+ or +/−) under the control of the Prx1 promoter, both on a C57BL/6
background. All mesenchymal lineage cells in the developing mouse
limb bud are derived from Prx1-expressing cells, and the Prx1 promoter
is active in undifferentiated osteochondral progenitor cells [32]. There-
fore, in this model (Prx1-Cre;Jag1f/f) Jag1 is conditionally deleted in
progenitor cells of the limb-bud prior to skeletal development, as well
as all of their progeny (Supplemental Fig. 1). WT mice for comparison
are Prx1-Cre;Jag1+/+ or Prx1-Cre;Jag1f/+.
Jag1f/f mice (C57BL/6 background) were also crossed with mice
expressing Cre recombinase (+/+ or +/−) from the 2.3 kb fragment of
the Col1a1 promoter known as Col2.3 (Col2.3-Cre;Jag1f/f) on a CD1 back-
ground. The Col2.3 promoter is active in committed osteoblasts, but not
early-stage osteoprogenitors, throughout the bone, periosteum and
growth plate [33,34]. Therefore, in this model (Col2.3-Cre;Jag1f/f) Jag1
is conditionally deleted in committed osteoblasts and their progeny.
WT mice for comparison are Col2.3-Cre;Jag+/+ or Col2.3-Cre;Jag1f/+ on
the same C57BL/6;CD1 genetic background.
Dominant Negative Mastermind-like (dnMAML) (Prx1-Cre;
dnMAML+/−) transgenic mice and littermate controls on a C57BL/6
backgroundwere also utilized in this study as a canonical Notch signal-
ing antagonist. An establishedmodel in theﬁeld for over a decade, these
animals experience Notch inhibition [35]. Following (+/+ or +/−) Cre-
mediated deletion of a ﬂoxed stop cassette, these animals express a
truncated dnMAML-GFP fusion protein that contains the NICD-RBPjκ
complex-binding NICD domain but lacks its co-activator recruiting
function. Therefore, dnMAML mice lose canonical Notch signaling
just prior to gene transcription [35–37]. N90% of cell culture puriﬁed
osteoprogenitor cells express dnMAML-GFP and GFP is greatly upregu-
lated (50-fold). Our previous results show dnMAML expression in frac-
ture decreases Hes and Hey and markers of osteoblast differentiation
[37].2.2. Experimental design
Femurs were harvested for micro-computed tomography (μCT)
analysis of bone formation from Prx1-Cre;Jag1f/f, Col2.3-Cre;Jag1f/f or
dnMAML mice with respective littermate controls at 2 months
(8 weeks) of age (n = 6–10). Additional femurs were collected from
Prx1-Cre;Jag1f/f and control mice at 9 months of age (n = 7–12) and
from dnMAML mice at 6 months (n = 3–10).
RNA fromwhole tibiae (including cortical bone, trabecular bone and
marrow) was generated for quantitative real-time polymerase chain
reaction (qPCR) analysis of gene expression in Prx1-Cre;Jag1f/f and
Col2.3-Cre;Jag1f/f mice with respective littermate controls at 2 months
of age. RNAwas also isolated from the tibial cortical bone compartment
(excluding trabecular bone andmarrow) from Prx1-Cre;Jag1f/f and con-
trol mice at 2 months (n = 3–5). Animals were separated by sex for
analysis based on the dimorphic intensities of observed phenotypes.2.3. Embryonic skeletons
Mouse embryos were stained with Alcian blue and alizarin red at
E18.5 in accordance with previously published methods [38].
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Sample tissues were placed in RNAlater solution (Life Technologies)
and stored at −80 °C until further processing. Specimens were then
thawed on ice and placed in Qiazol lysis reagent (Qiagen). Tissue was
homogenized using the Tissue Tearor (BioSpec Products) and mRNA
was extracted using the miRNeasy Mini Kit with DNase digestion
(Qiagen) to remove DNA contamination. RNA yield was determined
using a NanoDrop 1000 spectrophotometer (Thermo Scientiﬁc). One
μg of mRNA was reverse transcribed in 20 μL of cDNA using a High
Capacity RNA-to-cDNA Kit (Applied Biosystems). Gene expression was
quantiﬁed using a 7500 Fast Real-Time PCR system (Applied
Biosystems) from a total of 10 μL ofMasterMix perwell, which included
1× Fast SYBR Green (Applied Biosystems), forward and reverse primers
(0.45 μM), and 0.5 μL of cDNA. For each gene of interest, samples
were run in duplicate and control wells were run to rule out DNA con-
tamination and primer dimer binding. Proper amplicon production
was conﬁrmed by melt curve analysis. Data were normalized to the
housekeeping gene, β-actin, and presented as fold change expression
to WT whole bone, calculated using the formula 2−ΔΔC(t). β-actin C(t)
values were stable across treatment groups.2.5. Micro-Computed Tomography (μCT)
Femurs were scanned using a Scanco vivaCT40 μCT system with the
following parameters: 10.5 μm isotropic voxel size, 55kVp, 145 μA, 1000
projections per 180°, 200 ms integration time, forming 2-D transverse
reconstructed 2,048 × 2,048 pixel images. Cortical bone parameters
weremeasured by analyzing 50 slices (0.525mm) in themid-diaphysis.
This deﬁned region was the central portion between the proximal and
distal ends of the femur. A semi-automated contouring method was
used to determine the outer cortical bone perimeter. Brieﬂy, a user-de-
ﬁned contour was drawn around the cortical bone perimeter of the ﬁrst
slice. This initial estimate was then subjected to automated edge detec-
tion. This contour then served as the initial estimate for the next slice,
with the contouring process continued for all 50 slices. A ﬁxed, global
threshold of the maximum gray value was used to distinguish bone
from soft tissue and marrow. Trabecular bone parameters wereFig. 1.Morphology of the embryonic skeleton. Butterﬂy vertebrae develop by E18.5 in Col2.3-Cr
mice (frequency:0/5). Specimens are stained with Alcian blue and alizarin red.measured by analyzing 101 slices (1.06 mm) of the distal metaphysis.
Brieﬂy, the distal end of the analysis region was chosen to be
0.105 mm proximal to the end of the primary spongiosa in the marrow
cavity. This assured that only trabecular bone was analyzed. Starting at
this image, a user-deﬁned contour was drawn to include trabecular
bone within themarrow cavity and exclude cortical bone. User-deﬁned
contours were drawn every 10 slices (0.105 mm) and an automated
morphing program was used to interpolate the contours for all images
in between. A ﬁxed, global threshold of 23% of the maximum gray
value, which corresponds to 321.6 mg HA/cm3 was used to distinguish
trabecular bone from soft tissue andmarrow. A Gaussian low-pass ﬁlter
(σ= 0.8, support = 1) was used for all analyses.
2.6. Biomechanical testing
Femurs were loaded to failure in four-point bending at 0.5 mm/s in
the anterior-posterior direction using a servohydraulic testing machine
(858 Minibiox II; MTS Systems Corporation) with the posterior side in
tension between upper and lower supports that were 2.2 mm and
6.35mm apart, respectively. All boneswere tested at room temperature
and kept moist with PBS. Crosshead displacement was recorded by
using an external variable differential transducer (LVDT; Lucas
Schavitts), and load data were collected with a 50-lb. load cell
(Sensotec) at a sampling frequency of 2048 Hz. Load-displacement
curves were analyzed for whole bone stiffness, yield load, ultimate
load, elastic energy, plastic energy, total energy to failure, and displace-
ment ratio (ratio of failure displacement to yield displacement) using
custom computational code (MATLAB 7.11; Mathworks Inc.).
2.7. Cell culture
CFU-F assays were performed as described previously [39]. Brieﬂy,
whole marrow was ﬂushed from both tibiae and femurs of mice. Cells
were pelleted, resuspended in alpha-MEMwith 10% serum and penicil-
lin/streptomycin and then single cell suspensions plated at 4 million
cells per 60 mm dish in duplicate. Colonies were allowed to develop
for 12 days and then stained with Alkaline phosphatase with Fast red
as a counter stain. Colonies were enumerated in blinded fashion usinge;Jag1f/fmice (frequency: 3/6) but not inWT littermates (frequency:0/9) or Prx1-Cre;Jag1f/f
Fig. 2. qPCR analysis of Jag1-null bones. Gene expression of Notch pathway components (A) Jag1, (B) Hes1 and (C) Hey1, osteogenic genes (D) osteocalcin (Ocn), (E) osterix (Osx) and
(F) collagen type-I (Col1a1) and pro-osteoclastogenesis genes (G) receptor activator of nuclear factor kappa-B ligand (RANKL), (H) osteoprotegerin (Opg) and (I) tartrate-resistant acid
phosphatase (TRAP). For all analyses, data are presented as fold change expression to each genotype's respective whole bone (Prx1-Cre;Jag1f/f or Col2.3-Cre;Jag1f/f) calculated using the
formula 2−ΔΔC(t) (*p b 0.050, #p b 0.100).
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(mMSC) data presented in Supplemental Fig. 6 was run in accordance
with previously published methods [40].
2.8. Statistical analysis
Homoscedastic Student's t-tests were used to compare each Jag1
knockout group to its respectiveWT control for all μCT and qPCR param-
eters (*p b 0.050, #p b 0.100). Biomechanical data were analyzed using
2-way ANOVA for each individual parameter with Bonferroni post hoc
tests between sexes.
3. Results
3.1. Jag1 hasminimal impact on skeletal development and spinal patterning
Neither Col2.3-Cre;Jag1f/f nor Prx1-Cre;Jag1f/f showed gross alter-
ations in long bone development and growth, or body weights
at harvest (data not shown). Qualitative analysis of growth platessimilarly did not demonstrate any obvious abnormalities (data
not shown). On the other hand, butterﬂy vertebrae, a phenotype
associated with ALGS, developed in some percentage of the Col2.3-
Cre;Jag1f/f mice (Fig. 1). This phenotype of butterﬂy vertebrae is well-
recognized in mice with genetic mutations in Notch signaling
since Notch genes govern vertebral segmentation [41]. Although
Col2.3 is generally considered a reliable osteoblast speciﬁc promoter
[33], off-target expression of the Cre recombinase and therefore knock-
out of Jag1 during embryonic spinal patterning likely caused this verte-
bral phenotype [34,42]. Consistent with the greater speciﬁcity of the
Prx1 promoter, Prx1-Cre;Jag1f/f mice did not develop this vertebral
defect.
3.2. Loss of Jag1 decreases Notch pathway and osteoblastic gene expression
Loss of Jag1 in osteochondral progenitor cells (Prx1-Cre;Jag1f/f)
resulted in reduced whole-bone expression of Jag1 and the Notch path-
way genes, Hes1 and Hey1, osteoblast markers Ocn, Osx and Col1a1, and
also decreased expression of the osteoclast regulators RANKL and Opg
Fig. 3. μCT analysis of trabecular bone in Prx1-Cre;Jag1f/fmice at 2months (females andmales) and 9months (males) of age: (A) representative images, (B) bone volume fraction (BV/TV),
(C) tissue mineral density (TMD), (D) trabecular number (Tb.N), (E) trabecular thickness (Tb.Th) and (F) trabecular separation (Tb.Sp) (*p b 0.050, #p b 0.100).
Fig. 4. μCT analysis of trabecular bone in Col2.3-Cre;Jag1f/f mice at 2 months (females and males) of age: (A) representative images, (B) bone volume fraction (BV/TV), (C) tissue mineral
density (TMD), (D) trabecular number (Tb.N), (E) trabecular thickness (Tb.Th) and (F) trabecular separation (Tb.Sp) (*p b 0.050, #p b 0.100).
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Fig. 5. μCT analysis of cortical bone in Prx1-Cre;Jag1f/fmice at 2months (females andmales) and 9months (males) of age: (A) representative 2-D images, (B) total area (Tt.Ar), (C)marrow
area (M.Ar), (D) cortical bone area (Ct.Ar) and (E) cortical bone thickness (Ct.Th) (*p b 0.050, #p b 0.100).
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groups (Supplemental Fig. 2). Increased TRAP (pro-osteoclastogenesis)
expression was only observed in cortical bone samples. Surprisingly,
expression of osteoblast marker genes and the Notch targets Hes1 and
Hey1 were unchanged in cortical bone. Differences in expression levels
ofOcn (osteoblastmarker) and RANKL (pro-osteoclastogenesis) lost sta-
tistical signiﬁcance when Jag1 knockout was performed only incommitted osteoblasts (Col2.3-Cre;Jag1f/f). On the other hand, the mag-
nitudes of Osx and Col1a1 downregulation were greater in Col2.3-
Cre;Jag1f/f mice, and CcnD1 gene expression was downregulated only
in the Col2.3-Cre;Jag1f/f group (Supplemental Fig. 3). To summarize
the gene expression data, loss of Jag1 signaling in osteoblast lineage
cells results in broad reduction in Notch-pathway and osteoblastic
marker gene expression in whole bone.
Fig. 6. μCT analysis of cortical bone in Col2.3-Cre;Jag1f/f mice at 2 months (females and males) of age: (A) representative 2-D images, (B) total area (Tt.Ar), (C) marrow area (M.Ar),
(D) cortical bone area (Ct.Ar) and (E) cortical bone thickness (Ct.Th) (*p b 0.050, #p b 0.100).
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manner
Jag1 positively regulates trabecular bone mass. Male mice in
the Prx1-Cre;Jag1f/f group presented with decreased trabecular
number and increased trabecular spacing at 2 months that persisted
through 9 months, however, a loss of trabecular bone volume fraction
was not evident until the later time point (Fig. 3). Accompanyingthese changes was reduction in tissue mineral density. Similarly,
male mice in the Col2.3-Cre;Jag1f/f group demonstrated decreased
trabecular number and thickness and increased trabecular spacing
at 2 months of age (Fig. 4D–F). The particularly low expression of
osteoblast marker genes in the Col2.3-Cre;Jag1f/f group relative to WT
is consistent with the earlier onset of trabecular volume fraction loss
and trabecular thickness in comparison to the Prx1-Cre;Jag1f/f group
(Fig. 4).
Fig. 7. Results of biomechanical testing: (A) stiffness, (B) failure load, (C) yield load and (D) total energy for Prx1-Cre;Jag1f/f bones versus their corresponding WT.
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deﬁcient mice to determine whether defects seen in bone mass could
be associated with alterations in progenitor number. Prx1-Cre;Jag1f/f
mice formed approximately twice as many CFU-F colonies as control
bone cells in an in vitro CFU-F assay (Supplemental Fig. 4). This result
suggests that the loss of Jag1-mediated Notch signaling increases the
intramedullary mesenchymal progenitor cell population size, despite
the apparent decrease in intramedullary bone formation.
3.4. Jag1 deletion promotes periosteal expansion of cortical bone
Increased total bone area, marrow area, cortical area, and cortical
thickness were observed in Prx1-Cre;Jag1f/f mice of both sexes (Fig. 5).
This phenotype was not present (males) or was present at a much
lower magnitude (females) in the Col2.3-Cre;Jag1f/f group (Fig. 6). Con-
sistentwith the increased cortical bonemass, Prx1-Cre;Jag1f/f bones had
greater stiffness and greater failure load during tensile testing (Fig. 7),
concurrent with the increased moment of inertia resulting from high
periosteal bone formation observed via μCT.
3.5. Disruption of canonical Notch signaling in mesenchymal progenitors
increases cortical bone mass
The inﬂuence of Jag1 in Prx1-Cre expressing cells could be through
heterotypic signaling, i.e. Jag1 expressed on the mesenchymalprogenitor cell binding to Notch receptor on an adjacent, non-mesen-
chymal cell or Jag1 could be signaling in a homotypic manner, within
the mesenchymal lineage cells. To address this concern we blocked ca-
nonical Notch signaling using the Prx1-Cre;dnMAML+/− system [35].
Our previous results show that dnMAML expression during fracture
healing decreases Hes/Hey target genes [37]. In 2-month-old dnMAML
mice, similar to the observation in the Prx1-Cre;Jag1f/f mice, there is an
increase in cortical bone mass due to periosteal expansion, but no
apparent change in trabecular bone mass (Fig. 8).
4. Discussion
ALGS patients with Jag1 deﬁciency have reduced bone mass and a
propensity for fracture [8]; however, since Jag1 deﬁciency also results
in hepatobiliary dysfunction, this systemic pathology could be responsi-
ble for the skeletal abnormalities. Jag1 is the most highly expressed
ligand in bone mesenchymal progenitor cells, and has variable effects
on osteoblast differentiation in vitro [40]; thus, it is imperative to deter-
mine the direct, cell-autonomous effects of Jag1 on bone mass in vivo.
We disrupted Jag1 expression in osteoblast progenitors using the
Prx1 and Col2.3 promoters and determined that Jag1 expression by
mesenchymal lineage cells has bone compartment-speciﬁc effects. In
cortical bone, the absence of Jag1 expression by (Prx1+) progenitor
cells, but not osteoblasts (Col2.3+), enhances periosteal bone expan-
sion and cortical bone mass. This phenotype is not observed following
Fig. 8. μCT analysis of Prx1-Cre;dnMAML (A–E) trabecular and (F–H) cortical bone in females at 2 and 6months (at 2months: Prx1-Cre;dnMAML n=10, control n=6; at 6months: Prx1-
Cre;dnMAML n = 3, control n = 3) (*p b 0.050, #p b 0.100).
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suggest that Jag1 negatively regulates differentiation of mesenchymal
progenitor cells toward the osteoblast stage, but does not appear to
inﬂuence the anabolic function of already-differentiated osteoblasts
(Col2.3+) at the periosteal surface.
With respect to intramedullary trabecular bone, Jag1 disruption in
either (Prx1+) progenitor cells or in (Col2.3+) osteoblasts decreases
bone mass and osteoblast gene expression. This suggests that, in con-
trast to cortical bone, Jag1 positively regulates trabecular osteoblast
function. Indeed, the expression of Jag1 and the target gene Hey1 are
positively correlated with osteoblast gene expression (Supplemental
Fig. 5).
We further conclude that the inﬂuence of Jag1 on the cortical bone
phenotype is dependent upon Jag1-mediated canonical Notch signaling
within the mesenchymal lineage. dnMAML mice, with canonical Notch
signaling blocked in (Prx1+) progenitor cells, show cortical bone
changes consistent with disruption of Jag1. On the other hand, blocking
canonical Notch signaling in Prx1+ progenitor cells does not alter tra-
becular bone. This lack of an impact of dnMAML on trabecular bone
mass could reﬂect the fact that dnMAML, as a dominant negative, only
partially inhibits canonical signaling and its effectiveness is dependent
upon the relative signal strength. Indeed, it is feasible that the dnMAML
is not effectively suppressing Notch signaling within the mesenchymal
lineage within the trabecular compartment. We have established that
canonical Notch signaling in cortical bone is reduced relative to canon-
ical Notch signaling in whole bone, and perhaps this accounts for the
lack of an effect of the dnMAML on trabecular bone. Alternatively, the
impact of trabecular Jag1 signaling on bone mass could occur through
heterotypic signaling or through a non-canonical mediated pathway.
For example, there is evidence that Jag1 could signal in a non-canonical
manner within its own cell by reverse ligand cleavage of the intracellu-
lar domain independent of the Notch signaling pathway [43,44].
While the mechanism behind the change in cortical bone geometry
in Prx1-Cre;Jag1f/f mice is unknown, there are a variety of potential
explanations. Though derived from a common paraxial mesenchyme
precursor during development, the osteoblasts that form trabecular
bone and those that form periosteal bone are phenotypically distinctand under the control of differing regulatory pathways. Thus, it perhaps
is not unexpected that the role of Jag1may be different in the periosteal
bone relative to trabecular bone. Indeed, basal expression levels of
Notch target genes in the cortical compartment are reduced relative to
whole bone, suggesting that Notch signaling is already lower in normal
mature cortical bone. Coincident with this lower basal level of Notch
target gene expression, the disruption of Jag1 in cortical bone did not
alter Notch target gene expression of Notch targets or osteoblastogenic
markers. This is consistent with the absence of a cortical bone pheno-
type in the Col2.3-Cre;Jag1f/f mice. It should be noted that one limitation
of the gene expression analysis is that thewhole bone and cortical bone
RNA samples represent heterogeneous cell populations. Future studies
focusing on molecular regulation at the cellular level should focus on
purifying RNA in a cell-speciﬁc manner, for instance using laser capture
or ribosomal capture techniques.
One explanation for the cortical phenotype is that compensatory
effects following the reduction in trabecular bone mass in knockout
mice could trigger a mechanical adaptation response on the periosteal
bone surface independent of the Notch pathway; however, one would
then expect that the Col2.3-Cre;Jag1f/f mice would also have a more
pronounced cortical phenotype. Alternatively, Jag1 disruption in cells
outside of the cortical compartment may stimulate cortical bone at a
distance [45,46].We initially hypothesized that deletion of oneNotch li-
gand may be functionally compensated via upregulation of other Notch
ligands, but this does not appear to be the case. In vivo data from both
knockout mice and in vitro data from a WT mMSC cell pool suggest
that Jag1 participates in a positive feedback circuit: Jag1 knockout
causes maintenance or downregulation of other Notch ligands, while
Jag1-induced Notch activation results in upregulation of Jag1 gene
expression (Supplemental Fig. 6). Finally, the expansion of the
marrow osteoprogenitor pool (CFU-F) in Prx1-Cre;Jag1f/f mice may
provide some insight into how the periosteum becomes thickened
and expanded. Jag1 activity may not only increase the marrow
osteoprogenitor pool but also increase periosteal osteoblast progenitor
pool.Morework is needed to fully elucidate themechanisms underlying
the observed phenotypes, and particularly to differentiate cortical and
trabecular effects.
73D.W. Youngstrom et al. / Bone 91 (2016) 64–74It is notable that while the cortical phenotype is present in the Prx1-
Cre;Jag1f/f mice, but is limited in the Col2.3-Cre;Jag1f/f mice, the trabecu-
lar bone phenotype in the Prx1-Cre;Jag1f/f mice is less pronounced rela-
tive to the Col2.3-Cre;Jag1f/f mice. One explanation for this observation
could be the expanded pool of marrow mesenchymal progenitor cells
in the Prx1-Cre;Jag1f/f mice. Jag1 expression not only regulates
osteoblast function, but also serves to regulate the mesenchymal
progenitor pool. This is consistent with the ﬁndings of the Hilton
group [15,31]. However, in those models there is essentially complete
Notch signaling ablation, whereas with Jag1 disruption, signaling from
other ligands can still occur within the targeted lineage. CcnD1 was sig-
niﬁcantly downregulated in Col2.3-Cre;Jag1f/f whole bone, perhaps due
to direct activity of Notch on the CcnD1 promoter [47], potentially lead-
ing to cell cycle disruption and favoring progenitor cell differentiation
over self-renewal [48].
Prx1-Cre;Jag1f/f trabecular and cortical bone phenotypes were pres-
ent in both males and females, although the trabecular phenotype was
more pronounced in the males. Similarly, trabecular phenotypes in
Col2.3-Cre;Jag1f/f mice were more pronounced in males, but cortical
bone phenotypes were more pronounced in the Col2.3-Cre;Jag1f/f fe-
males. It is notable that gender dimorphism in bone phenotypes has
been documented in a variety of other settings [50]. Bone is particularly
sensitive to sex-steroids and differences between Jag1 signaling
intersecting with sex-steroid inﬂuences could account for the gender
differences [51]. However, there are no known gender differences in
the skeletal phenotype of ALGS.
In conclusion,we demonstrate that Notch signaling through Jag1 has
highly contextual, bone compartment-speciﬁc effects. Jag1 represses
cortical bone expansion by signaling in a homotypic manner in Prx1+
mesenchymal progenitors and their progeny. Conversely, Jag1
promotes increased bone mass in the trabecular compartment, and
may not require homotypic signaling. Jag1 therefore represents an in-
teresting therapeutic target for complex fracture healing, age-associated
mineral loss and disorders of bone metabolism including ALGS.
Furthermore these ﬁndings suggest that Jag1 dysfunction within bone
directly contributes to the skeletal symptoms of ALGS, and may not be
contingent on comorbid chronic liver disease. While there may not
appear to be complete concordance between the ﬁndings in this
mouse model and human Alagille syndrome patients, the bone
phenotype of ALGS patients is not well described. Osteopenia based
on radiography is described, but a thorough examination of trabecular
and cortical morphometrics has not been completed. This will require
a pQCT study, which is currently underway by the authors. Alternative-
ly, it could be that the role of Jag1 in mouse bone and human bone are
somewhat different, and that the imposition of liver abnormalities on
the human bone further exacerbates Jag1 bone speciﬁc effects.
Additional studies are required to dissect the spatiotemporal molecular
dynamics of Notch-induced osteoblastogenesis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bone.2016.07.006.Disclosures
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